VivoSeq
Oncology

Refractory B-Cell Non-Hodgkin Lymphoma

5

Pipeline Programs↗

5

Active Trials↗

4

Companies Involved↗

Refractory B-Cell Non-Hodgkin Lymphoma is an early-stage landscape with 5 programs across 4 companies. The most active players are Roche, Merck & Co., BeOne Medicines.

Intelligence

Pipeline Metrics

Competitive Density

32/100

Pipeline Velocity

15/100

Mech. Concentration

50/100

Completion Rate

N/A

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Roche logo

Roche

2 programs

Phase 1Merck & Co. logo

Merck & Co.

1 program

Phase 1B

BeOne Medicines

1 program

Phase 1Incyte logo

Incyte

1 program

Phase 2

Pipeline

Programs by Phase

Preclinical
No programs
Phase 14

MK-1045

Merck & Co.

Zanubrutinib

BeOne Medicines

Rituximab

Roche

Obinutuzumab

Roche

Phase 21

Pemigatinib

Incyte

Phase 3
No programs
Approved
No programs

Analysis

Modality Breakdown

4programs
Small molecule250%
Monoclonal antibody250%

Modality classified for 100% of 5 pipeline programs.

Analysis

Trial Status

5

clinical trials

Active, not recruiting3 · 60%
Not yet recruiting1 · 20%
Recruiting1 · 20%

Clinical Trials

Trial Activity

Allogeneic Natural Killer T-Cells Expressing CD19 Specific Chimeric Antigen Receptor and Interleukin-15 in Relapsed or Refractory B-Cell Malignancies
Active, not recruiting·BBaylor College of Medicine·Phase 1·NCT03774654·13 enrolled
A Real-World Study on the Efficacy and Safety of Bispecific Antibody in the Treatment of Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
Not yet recruiting·—·N/A·NCT07695896·200 enrolled
PERFORM: A Phase II Study of Pemigatinib in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphomas
Active, not recruiting·UUniversity of Utah·Phase 2·NCT06300528·1 enrolled
A Phase 1b Study of Tazemetostat in Combination With Zanubrutinib and Anti-CD20 Monoclonal Antibody in Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphomas (TARZAN Trial)
Active, not recruiting·UUniversity of Utah·Phase 1·NCT06824701·24 enrolled
An Open-Label, Dose Escalation Phase 1a Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of MK-1045 (CN201) in Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
Recruiting·MMSD R&D (China) Co., Ltd.·Phase 1·NCT06189391·100 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)